EGFR and adenocarcinoma: Subsequently, we further conducted stratified analysis, finding that among the adenocarcinoma cases, patients with EGFR 19 deletion mutation have longer OS than the wide-type (36.0 months versus 19.0 months, p = 0.046, Figure 3).